dendritic cell-gp100-mart-1 antigen vaccine
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 1999 (NCT00004025)
Timeline
Indications
Studied for
Mechanism of action
- Melanocyte protein PMELImmunity, active
PMEL immunity, active
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- dendritic cell-gp100-mart-1 antigen vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00019890 | Phase 2 | Mar 2, 2007 | National Cancer Institute (NCI) |
| NCT00004025 | Phase 1/Phase 2 (Phase 2) | Mar 1, 1999 | Genzyme |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genzyme | For profit | 1 | 1 | 1 | 1999 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2007 |
2 organizations
Page 1 / 1